An observational study in Ischemic Stroke, sponsored by General Hospital of Shenyang Military Region. Recruiting at 1 site in China. Open to participants aged 18 Years to 80 Years. Per ClinicalTrials.gov, last updated 2026-09-17.
Sponsored by General Hospital of Shenyang Military Region · Observational
Acute ischaemic stroke (AIS) results in high rates of neurological morbidity and mortality, especially in patients with large vessel occlusion (LVO). Endovascular therapy (EVT) has been approved as the most effective treatment for patients with LVO , but about half patients undergoing EVT did not achieve good outcome. The mechanisms of poor prognosis are complex. How to accurately identify serological biomarkers related to patients' clinical prognosis is an important research topic nowadays.
2,612 studies on the registry are indexed under Ischemic Stroke; 971 are open to participants now.
This study's planned enrollment of 800 is above the median of 300 across 771 observational studies indexed under Ischemic Stroke.
Browse Ischemic Stroke studies →General Hospital of Shenyang Military Region is the lead sponsor of 78 studies on the registry; 33 are open to participants now.
Counted across the registry records on this site, refreshed daily.
Patients with acute anterior circulation large vessel occlusion within 24 hours of onset who will receive endovascular treatment
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorised to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorised to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraindication
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ALT and AST (liver enzymes)
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ULN (upper limit of normal)
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
all patients with anterior circulation large vessel occlusion will receive endovascular treatment.
Dynamic changes in serum biomarkers after endovascular treatment
These biomarkers will be identified based on proteomic methods
Time frame: from the baseline to immediately, 30 minutes, 6 hours, and 24 hours after endovascular treatment
favourable functional outcome, defined as modified Rankin Scale (mRS) 0-2
mRS ranges from 0-6, high score means poor outcome
Time frame: 90±7 days
excellent functional outcome, defined as modified Rankin Scale (mRS) 0-1
mRS ranges from 0-6, high score means poor outcome
Time frame: 90±7 days
distribution of modified Rankin Scale (mRS) score
mRS ranges from 0-6, high score means poor outcome
Time frame: 90±7 days
early neurological improvement, defined as 4 or more decrease in National Institute of Health stroke scale (NIHSS)
NIHSS ranges from 0-22, with high score meaning severe neurological deficit.
Time frame: 24±8 hours
changes in National Institute of Health stroke scale (NIHSS)
NIHSS ranges from 0-22, with high score meaning severe neurological deficit.
Time frame: 24±8 hours
symptomatic intracranial hemorrhage (sICH)
sICH is defined as an increase in 4 or more points on the NIHSS
Time frame: 24±8 hours
occurence of new stroke or other vascular events
Time frame: 90±7 days
the association between cerebral circulation time (CCT) and clinical outcomes
CCT is defined as the time from the appearance of contrast at the siphon segment of the internal carotid to the end of the arterial phase during DSA on the anteroposterior and lateral image in anterior circulation LVO; clinical outcomes include changes in NIHSS and mRS
Time frame: 24±8 hours, 10±2 days, 90±7 days
the association between serum biomarkers and clinical outcomes
serum biomarkers include those in different timepoints or their dynamic changes; clinical outcomes include changes in NIHSS and mRS
Time frame: 24±8 hours, 10±2 days, 90±7 days
the association between serum biomarkers and status of vessel recanalization
serum biomarkers include those in different timepoints or their dynamic changes; the status of vessel recanalization is determined by modified thrombolysis in cerebral infarction
Time frame: 24±8 hours, 10±2 days, 90±7 days
Plan to share: Undecided
No publications or documents are linked to this record.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
No contact was published for this record. The registry link below has the sponsor’s details.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
General Hospital of Shenyang Military Region